All articles tagged with #amyloid
Researchers presented at the Alzheimer’s Association International Conference that brief, wakeful CO2 bursts may stimulate the brain’s glymphatic system, aiding clearance of tau and raising blood beta-amyloid temporarily; findings from a small 12-person study also reference breath-centered practices like yoga as potential contributors, but more research is needed to determine if this could slow cognitive decline.
A large-scale analysis of brain imaging from 17,017 older adults across five cohorts used the Centiloid standard to compare amyloid burden. The study found Hispanic participants generally have lower amyloid levels and a weaker link between APOE ε4 and amyloid than non-Hispanic whites with similar risk, implying Alzheimer’s biology may differ across populations and highlighting the need for diverse data to guide treatments.
A Mayo Clinic study of 2,082 participants found two broad windows where dementia-related changes begin long before diagnosis: cognition and amyloid changes start in the 50s–60s, followed by tau changes and blood biomarkers (GFAP, NfL, p-tau) in the late 60s to early 70s, along with brain atrophy. This could enable earlier detection and screening approaches, even though no single test currently exists.
Alzheimer's blood tests that detect amyloid or tau are being considered for early risk assessment, but doctors say their predictive value for asymptomatic people is uncertain, with potential false positives/negatives and no clear benefit from early intervention; FDA has cleared two tests for symptomatic patients, not for screening; patient interest is high, with surveys showing many would take a test if advised, though distress is common.
FDA plans advisory panels to reconsider compounded peptides; a sweeping Cochrane review revives debates over amyloid-targeting Alzheimer’s drugs; Roche will run another Elevidys trial outside the U.S. as Sarepta markets it domestically; Lilly’s Foundayo GLP-1 pill shows non-inferiority to insulin glargine with a FDA submission planned by the end of Q2.
A Cochrane review of 17 trials with over 20,000 people with mild cognitive impairment or early dementia found that seven anti-amyloid drugs, including donanemab and lecanemab, do not deliver a clinically meaningful benefit, even though they reduce brain amyloid. The findings challenge the idea that removing amyloid improves patient outcomes and have fueled ongoing debate over the amyloid hypothesis and the drugs’ high costs and risks.
A Cochrane Collaboration analysis of 17 trials involving over 20,000 people finds that amyloid-clearing Alzheimer's drugs slow decline but do not meaningfully improve patients’ lives, while carrying risks and costing up to £90,000 for an 18‑month course; the findings have sparked debate among experts, with some arguing for nuanced interpretation and others defending potential benefits, and the NHS continuing not to fund them.
A large USC-led study from the HABS-HD cohort finds early Alzheimer’s biomarkers differ by race/ethnicity: Black and Hispanic participants showed higher tau in memory-related brain regions even when amyloid levels were similar to White participants, and the amyloid–cognition link varied by group. Scanner limitations and social determinants of health may also influence readings, underscoring the need for population-tailored diagnostics and more inclusive research.
Harvard researchers show lithium naturally exists in the brain and supports neuron function; lithium depletion is an early Alzheimer’s change and is reduced when amyloid plaques bind lithium. In mice, losing brain lithium accelerates disease, while a lithium orotate compound can prevent or reverse pathology, prompting planned clinical trials; researchers caution against self-medicating until trials establish safety and efficacy.
A new blood test for Alzheimer's disease, measuring tau and amyloid proteins, offers 90% accuracy in early detection, potentially transforming diagnosis and care by providing a faster, less invasive, and more accessible tool especially useful in primary care settings.
Atrium Health Wake Forest Baptist in Winston-Salem has treated its first patient with the FDA-approved Alzheimer's medication, Lecanemab, marking the first Alzheimer's drug approval in over 20 years. The medication slows the progression of the disease by removing amyloid, a protein in the brain believed to contribute to memory loss. However, it is only effective for those with mild cognitive impairment or mild dementia due to Alzheimer's, and not for those with more advanced dementia.
Researchers are revisiting the development of vaccines for Alzheimer's disease following recent successes in drug treatments that remove toxic proteins from the brain. Clinical trials are underway or completed for at least seven Alzheimer's vaccines that target the disease-related proteins beta amyloid or tau. The renewed interest in vaccines comes after a promising first attempt over 20 years ago was abandoned due to life-threatening brain inflammation. Scientists believe they now understand what went wrong and are testing new vaccines that provoke an immune response without causing excess inflammation. Vaccines could offer a cheaper and easier-to-administer option for the millions of people affected by Alzheimer's.
The recent hype surrounding new Alzheimer's drugs that target amyloid, a protein thought to cause the disease, may be unwarranted. While these drugs have shown some ability to slow cognitive decline, the benefits are minimal and may not be noticeable to doctors or patients. Additionally, the drugs come with significant side effects, including brain bleeding and swelling, and are prohibitively expensive. The trials for these drugs were highly selective, excluding patients with other brain pathologies or medical problems, raising concerns about their effectiveness in real-world clinical settings. Furthermore, the drugs were tested on patients in the earliest stages of the disease, and even with amyloid clearance, patients still declined rapidly. Given these shortcomings, it may be time to explore alternative treatment options for dementia beyond the anti-amyloid drug pathway.
A new blood test that looks at the activity of astrocytes, star-shaped brain cells in the blood, may help identify individuals at risk for Alzheimer’s before they show any signs of the disease, according to a study published in the journal Nature Medicine. Only patients whose brains showed a combination of "abnormally reactive" astrocytes and high accumulations of amyloid went on to develop cognitive symptoms of the disease. The blood test results could be a game changer in identifying candidates at risk for Alzheimer’s disease for future research studies.
A study by the University of Pittsburgh claims that Alzheimer's disease can be detected using a simple blood test. The study found that patients who go on to develop Alzheimer's also have indicators in their blood that immune cells called astrocytes are activated. These star-shaped immune cells supply the brain with nutrients and oxygen and protect it from pathogens. The team tested the blood of more than 1,000 cognitively healthy older adults with and without amyloids in their brain. They found that only those who had a combination of amyloid and blood markers of abnormal astrocyte activity would progress to symptomatic Alzheimer's in the future.